Advertisement
ACB vs EVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and EVO is a StrongBuy.
ACB's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Indicator for ACB moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In 17 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACB as a result. In 82 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
ACB moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for ACB moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +17.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 175 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 97 of 116 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.477) is normal, around the industry mean (10.407). P/E Ratio (-2.046) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
EVO in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 12, 2026
EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 37 cases where EVO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EVO's RSI Oscillator exited the oversold zone, 29 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Following a +9.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 185 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVO as a result. In 88 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EVO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (10.407). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ACB | EVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 72 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 96 | |
PRICE GROWTH RATING 1..100 | 41 | 65 | |
P/E GROWTH RATING 1..100 | 90 | 1 | |
SEASONALITY SCORE 1..100 | 11 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACB's Valuation (25) in the Pharmaceuticals Other industry is significantly better than the same rating for EVO (92) in the null industry. This means that ACB’s stock grew significantly faster than EVO’s over the last 12 months.
ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
ACB's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as EVO (96) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
ACB's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as EVO (65) in the null industry. This means that ACB’s stock grew similarly to EVO’s over the last 12 months.
EVO's P/E Growth Rating (1) in the null industry is significantly better than the same rating for ACB (90) in the Pharmaceuticals Other industry. This means that EVO’s stock grew significantly faster than ACB’s over the last 12 months.
| ACB | EVO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 73% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 71% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 67% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 77% |
| Advances ODDS (%) | 17 days ago 76% | 2 days ago 68% |
| Declines ODDS (%) | 4 days ago 84% | 7 days ago 80% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACB’s FA Score shows that 1 FA rating(s) are green while EVO’s FA Score has 1 green FA rating(s).
- ACB’s FA Score: 1 green, 4 red.
- EVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACB’s TA Score shows that 4 TA indicator(s) are bullish while EVO’s TA Score has 5 bullish TA indicator(s).
- ACB’s TA Score: 4 bullish, 6 bearish.
- EVO’s TA Score: 5 bullish, 3 bearish.
Price Growth
ACB (@Pharmaceuticals: Generic) experienced а -5.04% price change this week, while EVO (@Pharmaceuticals: Generic) price change was +8.45% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
ACB is expected to report earnings on Nov 04, 2026.
EVO is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.
| Ticker / NAME | Correlation To ACB | 1D Price Change % | ||
|---|---|---|---|---|
| ACB | 100% | +0.25% | ||
| CGC - ACB | 69% Closely correlated | -1.00% | ||
| TLRY - ACB | 65% Loosely correlated | +0.34% | ||
| SNDL - ACB | 65% Loosely correlated | +0.78% | ||
| OGI - ACB | 64% Loosely correlated | -0.43% | ||
| CRON - ACB | 59% Loosely correlated | +1.62% | ||
More | ||||
EVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To EVO | 1D Price Change % | ||
|---|---|---|---|---|
| EVO | 100% | -1.28% | ||
| SNDL - EVO | 42% Loosely correlated | +0.78% | ||
| PRGO - EVO | 35% Loosely correlated | +2.89% | ||
| SUPN - EVO | 29% Poorly correlated | +2.09% | ||
| ACET - EVO | 26% Poorly correlated | -4.68% | ||
| ACB - EVO | 25% Poorly correlated | +0.25% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| THLV | 31.57 | -0.06 | -0.19% |
| THOR Equal Weight Low Volatility ETF (THLV) | |||
| MSSM | 57.31 | -0.20 | -0.34% |
| Morgan Stanley Pathway Small-Mid Cap Equity ETF (MSSM) | |||
| BBEU | 75.65 | -0.68 | -0.89% |
| JPMorgan BetaBuilders Europe ETF (BBEU) | |||
| FAN | 21.82 | -0.24 | -1.07% |
| First Trust Global Wind Energy ETF (FAN) | |||
| SUPP | 73.01 | -3.75 | -4.88% |
| TCW Transform Supply Chain ETF (SUPP) | |||